c-Met (METor MNNG HOS Transforming gene) is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor (HGFR; RTK class X, HGF receptor family). It was originally identified as an oncogene activated in vitro after treatment of a human osteogenic sarcoma (HOS) cell line. Currently, c-Met receives great interest for its role of aberrant signaling in tumorigenesis, particularly in the development of the invasive and metastatic phenotypes (see also Axon 2240). Signaling via the Met–HGF/SF pathway has been shown to lead to a wide range of biological activities including proliferation (mitosis), scattering (motility), and branching morphogenesis, embryological development, wound healing, tissue regeneration, angiogenesis, growth, invasion, and morphogenic differentiation.
 Molecular cloning of a new transforming gene from a chemically transformed human cell line. C.S. Cooper, M. Park, D.G. Blair et al. Nature 1984, 311, 29–33.
 M. Jeffers, L. Schmidt, N. Nakaigawa, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA. 1997, 94, 11445–11450.
|Axon ID||Name||Description||From price|
|1916||AMG 208||Inhibitor of c-MET receptor tyrosine kinase (RTK)||€110.00|
|2368||Amuvatinib||RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met||€105.00|
|1838||ARQ 197||c-MET tyrosine kinase Inhibitor||€95.00|
|1819||Cabozantinib S-malate||Inhibitor of multiple receptor tyrosine kinases, specifically MET and VEGFR2||€85.00|
|1582||Foretinib||c-MET and VEGFR2 tyrosine kinase inhibitor||€90.00|
|1959||Golvatinib||Potent and orally available inhibitor of c-MET (HGFR) and VEGFR2||€95.00|
|2553||LY 2801653||Orally bioavailable multi-kinase inhibitor with potent activity against c-MET||€120.00|
|1660||PF 02341066||c-MET Inhibitor; NPM-ALK inhibitor||€80.00|
|1583||PF 04217903 mesylate||c-MET tyrosine kinase Inhibitor||€80.00|
|1914||SGX 523||ATP-competitive inhibitor of c-MET||€120.00|
|1581||SU 11274||ATP-competitive inhibitor of c-MET||€95.00|